secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001104659-23-112359
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 2.02, 3.02, 5.08, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE announces $88M PIPE funding and positive clinical data for VYN201 and VYN202
--------------------------------------------------------------------------------

- Raised $88M gross from PIPE led by Access Biotechnology, with participation from healthcare investors.
- Phase 1b VYN201 vitiligo trial: 1.0% cohort 30.3% mean F-VASI reduction (p=0.0137), 2.0% cohort 39.0% (p=0.0077) vs 0.5%.
- VYN202 preclinical: 95% PASI reduction in psoriasis model; 71% reduction in rheumatoid arthritis signs/symptoms.
- Preliminary cash $15.5M as of Sep 30, 2023; with PIPE proceeds pro forma $103.7M.
- Next steps: Phase 2b VYN201 in vitiligo in 1H2024; Phase 1a VYN202 trial expected Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923112359/0001104659-23-112359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923112359/tm2329331d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-112359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer